| Accession |
PRJCA012405 |
| Title |
A randomized, double-blind, placebo-controlled, single-dose, dose-escalating Phase Ia clinical study to evaluate the safety, tolerability and pharmacokinetic profile of TG103 in healthy subjects |
| Relevance |
Medical |
| Data types |
demographic data
|
| Organisms |
Homo sapiens
|
| Description |
This study adopts a single-center, randomized, double-blind, placebo-controlled, dose-escalating clinical trial design in selected healthy Chinese adult subjects to evaluate the safety and tolerability, pharmacokinetic and pharmacodynamic characteristics of a single subcutaneous injection of TG103. |
| Sample scope |
Demographic data of Healthy Chinese subjects |
| Release date |
2022-10-10 |
| Grants |
| Agency |
program |
Grant ID |
Grant title |
| CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd
|
|
N
|
|
|
|
| Submitter |
Jangli
Jin (jiangli905@sina.com)
|
| Organization |
China-Japan Friendship Hospital |
| Submission date |
2022-10-10 |
